Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAU pseudogene 2 (FAUP2) is a non-coding genomic sequence classified as a pseudogene of the FAU gene, annotated by some databases as RPS30_1_440[1][3]. Unlike its parent gene FAU, which encodes a fusion of a ubiquitin-like protein (fubi) and ribosomal protein S30—a component of the 40S ribosomal subunit—FAUP2 does not encode a functional protein. While pseudogenes can sometimes play roles in gene regulation or act as sources of genetic material for gene conversion events, the specific functional significance of FAUP2 has not been established[2][3]. It is not considered a conventional drug target, receptor, enzyme, transporter, or transcription factor. In summary, FAUP2 is a pseudogene with no evidence supporting its role as a therapeutic target, and there is no current evidence for involvement in disease, pharmacology, or as a biomarker. Inclusion as a drug target would be incorrect based on current knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FAU pseudogene 2 (FAUP2).